Teva May Buy Celltrion - Implications for Celltrion & Celltrion Healthcare
How should we interpret Teva's potential acquisition of Celltrion? Is this for real? Well, Teva may still be very interested in acquiring Celltrion...
345 Views
More Harsh Reality from Teva
U.S. healthcare industry leaders from across the spectrum of industry segments continue to downplay the near-term adoption of biosimilars in the...
288 Views
Celltrion Healthcare IPO, Unlikely to Have Owner Premium Factor
Celltrion Healthcare, Celltrion (068270)’s overseas sales and marketing unit, decided to be listed in KOSDAQ (instead of Korea’s main bourse) as...
427 Views
Bioepis Details Don't Support the Valuation
We are following up on our previous post on the proposed listing of Samsung BioLogics US$9 Billion Valuation Is Rarefied Air  in response to...
372 Views
SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
3.6k Views